Chemistry:Sotatercept
From HandWiki
| Clinical data | |
|---|---|
| Other names | ACE-011, MK-7962-020 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Sotatercept (ACE-011, MK-7962-020) is a activin signaling inhibitor therapy drug being developed for pulmonary arterial hypertension.[1][2][3][4] It was initially developed to increase bone density[5] and has also been developed for anemia[6][7][8] and multiple myeloma.[9]
References
- ↑ Joshi, Sachindra R.; Liu, Jun; Bloom, Troy; Karaca Atabay, Elif; Kuo, Tzu-Hsing; Lee, Michael; Belcheva, Elitza; Spaits, Matthew et al. (12 May 2022). "Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension" (in en). Scientific Reports 12 (1): 7803. doi:10.1038/s41598-022-11435-x. ISSN 2045-2322. PMID 35551212. Bibcode: 2022NatSR..12.7803J.
- ↑ Humbert, Marc; McLaughlin, Vallerie; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; Hoeper, Marius M.; Preston, Ioana R.; Souza, Rogerio; Waxman, Aaron et al. (1 April 2021). "Sotatercept for the Treatment of Pulmonary Arterial Hypertension" (in en). New England Journal of Medicine 384 (13): 1204–1215. doi:10.1056/NEJMoa2024277. ISSN 0028-4793. PMID 33789009.
- ↑ "Role of Sotatercept in Management of Pulmonary Arterial Hypertension: The STELLAR Trial". American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Articles/2023/06/12/10/16/Role-of-Sotatercept-in-Management-of-PAH.
- ↑ Humbert, Marc; McLaughlin, Vallerie; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; Hoeper, Marius M.; Preston, Ioana R.; Souza, Rogerio; Waxman, Aaron B. et al. (1 January 2022). "Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension" (in en). European Respiratory Journal 61 (1). doi:10.1183/13993003.01347-2022. ISSN 0903-1936. PMID 36041750. PMC 9816418. https://erj.ersjournals.com/content/early/2022/08/04/13993003.01347-2022.
- ↑ Sherman, Matthew L.; Borgstein, Niels G.; Mook, Louisa; Wilson, Dawn; Yang, Yijun; Chen, Nianhang; Kumar, Ravindra; Kim, Kenneth et al. (November 2013). "Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women" (in en). The Journal of Clinical Pharmacology 53 (11): 1121–1130. doi:10.1002/jcph.160. ISSN 0091-2700. PMID 23939631.
- ↑ Lan, Zehao; Lv, Zhaohua; Zuo, Wanyun; Xiao, Yichao (September 2023). "From bench to bedside: The promise of sotatercept in hematologic disorders". Biomedicine & Pharmacotherapy 165: 115239. doi:10.1016/j.biopha.2023.115239. PMID 37516019.
- ↑ Komrokji, Rami; Garcia-Manero, Guillermo; Ades, Lionel; Prebet, Thomas; Steensma, David P; Jurcic, Joseph G; Sekeres, Mikkael A; Berdeja, Jesus et al. (February 2018). "Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial". The Lancet Haematology 5 (2): e63–e72. doi:10.1016/S2352-3026(18)30002-4. PMID 29331635.
- ↑ Raje, Noopur; Vallet, Sonia (1 October 2010). "Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss". Current Opinion in Molecular Therapeutics 12 (5): 586–597. ISSN 2040-3445. PMID 20886391. https://europepmc.org/article/med/20886391.
- ↑ Abdulkadyrov, Kudrat M.; Salogub, Galina N.; Khuazheva, Nuriet K.; Sherman, Matthew L.; Laadem, Abderrahmane; Barger, Rachel; Knight, Robert; Srinivasan, Shankar et al. (June 2014). "Sotatercept in patients with osteolytic lesions of multiple myeloma". British Journal of Haematology 165 (6): 814–823. doi:10.1111/bjh.12835. PMID 24650009.
 |  |
